SMS Pharmaceuticals Limited (SMSPHARMA.NS)
INR 239.35
(1.55%)
INR 239.35
(1.55%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 2.1 Billion INR | -10.11% |
| 2022 | 1.28 Billion INR | -28.94% |
| 2021 | 1.81 Billion INR | 0.0% |
| 2020 | 1.81 Billion INR | 42.47% |
| 2019 | 1.27 Billion INR | -5.16% |
| 2018 | 1.34 Billion INR | -1.35% |
| 2017 | 1.36 Billion INR | -42.77% |
| 2016 | 2.37 Billion INR | 11.45% |
| 2015 | 2.13 Billion INR | 10.1% |
| 2014 | 1.93 Billion INR | 28.8% |
| 2013 | 1.5 Billion INR | 250.49% |
| 2012 | 429.3 Million INR | -41.6% |
| 2011 | 735.14 Million INR | 7.07% |
| 2010 | 686.61 Million INR | 35.84% |
| 2009 | 505.45 Million INR | -4.47% |
| 2008 | 529.09 Million INR | -15.4% |
| 2007 | 625.41 Million INR | 2.04% |
| 2006 | 612.9 Million INR | 46.81% |
| 2005 | 417.48 Million INR | 18.09% |
| 2004 | 353.52 Million INR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 330.27 Million INR | -6.2% |
| 2023 Q3 | 507.04 Million INR | 1.12% |
| 2023 FY | 1.15 Billion INR | -10.11% |
| 2023 Q1 | 474.6 Million INR | 3.68% |
| 2023 Q2 | 501.4 Million INR | 5.65% |
| 2023 Q4 | 352.11 Million INR | -30.55% |
| 2022 Q1 | 155.74 Million INR | 86.19% |
| 2022 Q3 | 368.96 Million INR | 22.05% |
| 2022 Q4 | 457.76 Million INR | 24.07% |
| 2022 Q2 | 302.31 Million INR | 94.11% |
| 2022 FY | 1.28 Billion INR | -28.94% |
| 2021 FY | 1.81 Billion INR | 0.0% |
| 2021 Q2 | 635.59 Million INR | 0.88% |
| 2021 Q1 | 630.05 Million INR | 1.36% |
| 2021 Q3 | 462.42 Million INR | -27.25% |
| 2021 Q4 | 83.64 Million INR | -81.91% |
| 2020 Q1 | 328.71 Million INR | 35.68% |
| 2020 Q2 | 368.25 Million INR | 12.03% |
| 2020 FY | 1.81 Billion INR | 42.47% |
| 2020 Q4 | 621.56 Million INR | 25.39% |
| 2020 Q3 | 495.71 Million INR | 34.61% |
| 2019 Q4 | 242.27 Million INR | -25.74% |
| 2019 Q1 | 358.12 Million INR | 42.87% |
| 2019 Q2 | 346.82 Million INR | -3.15% |
| 2019 Q3 | 326.23 Million INR | -5.94% |
| 2019 FY | 1.27 Billion INR | -5.16% |
| 2018 FY | 1.34 Billion INR | -1.35% |
| 2018 Q3 | 368.99 Million INR | -2.64% |
| 2018 Q2 | 378.99 Million INR | 10.15% |
| 2018 Q1 | 344.08 Million INR | 0.0% |
| 2018 Q4 | 250.67 Million INR | -32.07% |
| 2017 FY | 1.36 Billion INR | -42.77% |
| 2016 Q2 | 601.12 Million INR | 9.23% |
| 2016 Q1 | 550.34 Million INR | -8.61% |
| 2016 FY | 2.37 Billion INR | 11.45% |
| 2015 Q2 | 527.25 Million INR | 16.44% |
| 2015 Q3 | 551.54 Million INR | 4.61% |
| 2015 Q4 | 602.19 Million INR | 9.18% |
| 2015 FY | 2.13 Billion INR | 10.1% |
| 2015 Q1 | 452.8 Million INR | -19.76% |
| 2014 Q1 | 411.2 Million INR | -24.67% |
| 2014 FY | 1.93 Billion INR | 28.8% |
| 2014 Q4 | 564.29 Million INR | 5.78% |
| 2014 Q3 | 533.45 Million INR | 24.31% |
| 2014 Q2 | 429.12 Million INR | 4.36% |
| 2013 Q3 | 428.04 Million INR | 14.8% |
| 2013 Q4 | 545.85 Million INR | 27.52% |
| 2013 FY | 1.5 Billion INR | 250.49% |
| 2013 Q2 | 372.86 Million INR | 139.06% |
| 2013 Q1 | 155.97 Million INR | 3639.19% |
| 2012 FY | 429.3 Million INR | -41.6% |
| 2012 Q2 | 110.59 Million INR | -49.76% |
| 2012 Q1 | 220.13 Million INR | 295.5% |
| 2012 Q3 | 99.51 Million INR | -10.02% |
| 2012 Q4 | -4.4 Million INR | -104.43% |
| 2011 FY | 735.14 Million INR | 7.07% |
| 2011 Q4 | 55.66 Million INR | -76.57% |
| 2011 Q3 | 237.58 Million INR | 0.0% |
| 2010 FY | 686.61 Million INR | 35.84% |
| 2009 FY | 505.45 Million INR | -4.47% |
| 2008 FY | 529.09 Million INR | -15.4% |
| 2007 FY | 625.41 Million INR | 2.04% |
| 2006 FY | 612.9 Million INR | 46.81% |
| 2005 FY | 417.48 Million INR | 18.09% |
| 2004 FY | 353.52 Million INR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Abbott India Limited | 26.16 Billion INR | 91.938% |
| Cipla Limited | 161.81 Billion INR | 98.696% |
| Gland Pharma Limited | 16.6 Billion INR | 87.294% |
| GlaxoSmithKline Pharmaceuticals Limited | 12.82 Billion INR | 83.547% |
| Kopran Limited | 2.12 Billion INR | 0.808% |
| Marksans Pharma Limited | 7.71 Billion INR | 72.655% |
| NGL Fine-Chem Limited | 1.23 Billion INR | -71.153% |
| Pfizer Limited | 9.9 Billion INR | 78.705% |
| Sanofi India Limited | 16.32 Billion INR | 87.079% |
| TTK Healthcare Limited | 2.68 Billion INR | 21.481% |